Taking oral glucocorticoids for 3 months or longer? Beware of osteoporosis!

March 27, 2012, International Osteoporosis Foundation

Millions of people around the world are prescribed glucocorticoids for a wide variety of inflammatory conditions, including, rheumatoid arthritis, asthma and inflammatory bowel diseases. Although they are effective and widely used, one of the potentially serious side effects of these medications is glucocorticoid-induced osteoporosis.

Osteoporosis is a serious condition in which bones become thinner and more fragile, making them more likely to break (fracture). Glucocorticoids can cause rapid bone loss in the first three to six months of treatment, leading to an increased risk of fracture. The greatest risk is seen for .

In their newly issued joint guidance paper for health professionals worldwide*, the International Osteoporosis Foundation (IOF) and the European Calcified Tissue Society (ECTS) have warned that specific precautions to help reduce the risk of bone loss and fracture must be taken for individuals on longer-term oral glucocorticoid therapy.

Professor Cyrus Cooper, chair of the IOF Committee of Scientific Advisors, commented, "Patients who are taking , or other glucocorticoids for three months or longer, should be advised to take appropriate measures to help reduce the accompanying bone loss. While osteoporosis itself is painless, resulting from osteoporosis can cause significant pain and lead to , and even higher risk of death."

WHO IS MOST AT RISK?

Generally, the higher the dose and the longer the glucocorticoid treatment continues, the higher the risk of fracture. People who take glucocorticoids orally or intravenously are at greater risk than those who inhale glucocorticoids for asthma, or apply lotions to the skin. However, using a high-dose steroid inhaler in the long term may also increase the risk of fracture. Injections of glucocorticoids into joints are not thought to affect the skeleton.

In terms of age, men and women over 70, and postmenopausal women and men over 50 who have had a previous fracture or take high doses of glucocorticoid, are at greater risk than younger men and women. Nevertheless, even younger people on glucocorticoids are advised to take precautions to help reduce bone loss. Dr. Tobie de Villiers, president of the International Menopause Society (IMS), commented, "Bone loss is a concern for all women around the age of menopause, and especially for the almost 5% of worldwide who take oral glucocorticoid therapy. The IMS encourages women to be aware of this potentially dangerous side-effect of therapy and to discuss what precautions can be taken with their doctors."

HOW TO PROTECT AGAINST GLUCOCORTICOID-INDUCED OSTEOPOROSIS

In their guidance paper*, the IOF and ECTS outline strategies and best practices for the management of bone health in patients on glucocorticoids.

As bone loss occurs rapidly in the first three to six months of treatment, patients should be taking preventive action from the start: they must ensure adequate amounts of calcium and protein in their diet, get enough vitamin D through safe exposure to sunlight and do regular weight-bearing exercise to keep bones and muscles active. It is also important that they stop smoking, and reduce alcohol intake. Supplement tablets, especially of vitamin D, may be prescribed as it is often difficult to ensure adequate levels through diet and sunlight.

Based on a clinical check-up and the results of bone mineral density (BMD) testing and a FRAX assessment ( http://www.shef.ac.uk/FRAX/ ), the doctor may decide to minimize the dose of glucocorticoids or use alternative medications. Some high risk patients may also be prescribed special bone protective therapy to reduce fracture risk. Patients on long-term glucocorticoid therapy should be monitored at appropriate intervals. This may include BMD testing, annual height measurements to check for possible height loss due to vertebral fractures, and, in patients receiving bone protective therapy, assessment to ensure compliance with therapy.

Professor Bente L. Langdahl, president of the European Calcified Tissue Society, stated, "It is important to note that no one should ever stop or reduce glucocorticoid treatment unless directed to by their doctor. At the same time, we advise that all patients and doctors be acutely aware of the need to monitor and take preventive action against as soon as glucocorticoid therapy begins."

Explore further: Consider bone test for many conditions, medications

More information: *A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis. S. Lekawasam, J. D. Adachi, D. Agnusdei, et al. for the Joint IOF-ECTS GIO Guidelines Working Group. Osteoporos Int DOI 10.1007/s00198-012-1958-1

The paper is freely accessible until June 26, 2012 at www.springerlink.com/content/w … 8602122/fulltext.pdf

Related Stories

Consider bone test for many conditions, medications

April 15, 2011
When it comes to bone health, age and family history of osteoporosis aren’t the only reasons to consider testing for fracture risk.

New IOF-ISCD review clarifies the use of FRAX in clinical practice

August 2, 2011
FRAX® is a computer-based algorithm developed by the World Health Organization Collaborating Centre for Metabolic Bone Diseases to help predict the 10-year risk of fragility fracture. Now with 34 specific country models, ...

Recommended for you

New long-acting approach for malaria therapy developed

January 22, 2018
A new study, published in Nature Communications, conducted by the University of Liverpool and the Johns Hopkins University School of Medicine highlights a new 'long acting' medicine for the prevention of malaria.

Virus shown to be likely cause of mystery polio-like illness

January 22, 2018
A major review by UNSW researchers has identified strong evidence that a virus called Enterovirus D68 is the cause of a mystery polio-like illness that has paralysed children in the US, Canada and Europe.

Creation of synthetic horsepox virus could lead to more effective smallpox vaccine

January 19, 2018
UAlberta researchers created a new synthetic virus that could lead to the development of a more effective vaccine against smallpox. The discovery demonstrates how techniques based on the use of synthetic DNA can be used to ...

Study ends debate over role of steroids in treating septic shock

January 19, 2018
The results from the largest ever study of septic shock could improve treatment for critically ill patients and save health systems worldwide hundreds of millions of dollars each year.

New approach could help curtail hospitalizations due to influenza infection

January 18, 2018
More than 700,000 Americans were hospitalized due to illnesses associated with the seasonal flu during the 2014-15 flu season, according to federal estimates. A radical new approach to vaccine development at UCLA may help ...

Flu may be spread just by breathing, new study shows; coughing and sneezing not required

January 18, 2018
It is easier to spread the influenza virus (flu) than previously thought, according to a new University of Maryland-led study released today. People commonly believe that they can catch the flu by exposure to droplets from ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.